✦ LIBER ✦

T.I.1 Targeted therapies for myotonic dystrophy

✍ Scribed by Thornton, C.

Book ID: 122585143
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 58 KB
Volume: 23
Category: Article
ISSN: 0960-8966
DOI: 10.1016/j.nmd.2013.06.717

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vascular-targeted therapies for Duchenne

Vascular-targeted therapies for Duchenne muscular dystrophy

✍ James P Ennen, Mayank Verma, Atsushi Asakura 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 307 KB

Myotonic dystrophy: time for evidence-ba

Myotonic dystrophy: time for evidence-based therapy

✍ Elliott, P. 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 301 KB

T.I.1 Pharmacological therapies in muscu

T.I.1 Pharmacological therapies in muscular dystrophies

✍ K.M. Flanigan 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Perspectives on gene therapy in myotonic

Perspectives on gene therapy in myotonic dystrophy type 1

✍ Jonathan J. Magaña; Bulmaro Cisneros 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB

Myotonic dystrophy type 1 (DM1) is an autosomal dominant neuromuscular disorder caused by a CTG expansion mutation located in the 3 0 untranslated region of the DMPK (DM1 protein kinase) gene. According to current evidence, mutant DMPK mRNAs containing the trinucleotide expansion are retained in the

Targeting nuclear RNA for in vivo correc

Targeting nuclear RNA for in vivo correction of myotonic dystrophy

✍ Wheeler, Thurman M.; Leger, Andrew J.; Pandey, Sanjay K.; MacLeod, A. Robert; Na 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 892 KB

T.I.2 Molecular therapies of Duchenne mu

T.I.2 Molecular therapies of Duchenne muscular dystrophy

✍ F. Muntoni 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 38 KB